Literature DB >> 2040694

The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia.

H Ahuja1, M Bar-Eli, Z Arlin, S Advani, S L Allen, J Goldman, D Snyder, A Foti, M Cline.   

Abstract

DNA from 135 patients with chronic myelogenous leukemia (CML) at various clinical stages and Philadelphia (Ph1) chromosome positive acute lymphoblastic leukemia was investigated for alterations in a variety of proto-oncogenes which have been implicated in the evolution of CML from its chronic phase to blast crisis. The most common genetic change found in the evolution of typical Ph1 chromosome positive CML to blast crisis was an alteration of the p53 gene involving either a rearrangement, a deletion, or a point mutation in the coding sequence of the gene. Alterations of the p53 gene were found in the myeloid and the rare megakaryocytic variant of blast crisis but were absent in the lymphoid leukemic transformants. Gross structural alterations were seen in 11 of 54 (20%) of myeloid or unknown phenotypes of blast crisis and in only 1 of 44 chronic phase cases. Eight examples of mutations in the open reading frame of the p53 gene at codons 49, 53, 60, 140, 202, 204, 238, and 239 were observed in blast crisis patients. Mutations in the N-RAS gene were rare in typical blast crisis (2 of 27 cases) but were found in megakaryocytic and Ph1 negative myeloid blast crisis. We concluded that heterogeneous alterations in the p53 gene and occasionally in the N-RAS genes accompany the evolution of chronic phase CML to blast crisis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2040694      PMCID: PMC296960          DOI: 10.1172/JCI115234

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  40 in total

1.  Chromosome studies on normal and leukemic human leukocytes.

Authors:  P C NOWELL; D A HUNGERFORD
Journal:  J Natl Cancer Inst       Date:  1960-07       Impact factor: 13.506

2.  Meth A fibrosarcoma cells express two transforming mutant p53 species.

Authors:  D Eliyahu; N Goldfinger; O Pinhasi-Kimhi; G Shaulsky; Y Skurnik; N Arai; V Rotter; M Oren
Journal:  Oncogene       Date:  1988-09       Impact factor: 9.867

3.  Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase.

Authors:  R K Saiki; D H Gelfand; S Stoffel; S J Scharf; R Higuchi; G T Horn; K B Mullis; H A Erlich
Journal:  Science       Date:  1988-01-29       Impact factor: 47.728

4.  Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining.

Authors:  J D Rowley
Journal:  Nature       Date:  1973-06-01       Impact factor: 49.962

5.  Specificity of proto-oncogene amplification in human malignant diseases.

Authors:  H Masuda; H Battifora; J Yokota; S Meltzer; M J Cline
Journal:  Mol Biol Med       Date:  1987-08

6.  Transforming genes in chronic myelogenous leukemia.

Authors:  E Liu; B Hjelle; J M Bishop
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

Review 7.  Molecular biology of chronic myelogenous leukemia.

Authors:  O Dreazen; E Canaani; R P Gale
Journal:  Semin Hematol       Date:  1988-01       Impact factor: 3.851

8.  Correlations between the clinical course, characteristics of blast cells, and karyotype patterns in chronic myeloid leukemia.

Authors:  E W Fleischman; E L Prigogina; M A Volkova; M A Frenkel; N A Zakhartchenko; L N Konstantinova; G P Puchkova; S A Balakirev
Journal:  Hum Genet       Date:  1981       Impact factor: 4.132

9.  Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas.

Authors:  S J Baker; E R Fearon; J M Nigro; S R Hamilton; A C Preisinger; J M Jessup; P vanTuinen; D H Ledbetter; D F Barker; Y Nakamura; R White; B Vogelstein
Journal:  Science       Date:  1989-04-14       Impact factor: 47.728

10.  Analysis of N-RAS exon-1 mutations in myelodysplastic syndromes by polymerase chain reaction and direct sequencing.

Authors:  M Bar-Eli; H Ahuja; N Gonzalez-Cadavid; A Foti; M J Cline
Journal:  Blood       Date:  1989-01       Impact factor: 22.113

View more
  13 in total

1.  Randomized study of imatinib for chronic myeloid leukemia: comparing standard dose escalation with aggressive escalation.

Authors:  Koichi Miyamura; Kazunori Ohnishi; Shigeki Ohtake; Noriko Usui; Chiaki Nakaseko; Hiroyuki Fujita; Shin Fujisawa; Toru Sakura; Hirokazu Okumura; Noriyoshi Iriyama; Nobuhiko Emi; Katsumichi Fujimaki; Sumihisa Honda; Yasushi Miyazaki; Tomoki Naoe
Journal:  Blood Adv       Date:  2019-02-12

Review 2.  The Hidden Pathogenesis of CML: Is BCR-ABL1 the First Event?

Authors:  Naranie Shanmuganathan; Susan Branford
Journal:  Curr Hematol Malig Rep       Date:  2019-12       Impact factor: 3.952

Review 3.  Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia.

Authors:  Susan Branford; Dennis Dong Hwan Kim; Jane F Apperley; Christopher A Eide; Satu Mustjoki; S Tiong Ong; Georgios Nteliopoulos; Thomas Ernst; Charles Chuah; Carlo Gambacorti-Passerini; Michael J Mauro; Brian J Druker; Dong-Wook Kim; Francois-Xavier Mahon; Jorge Cortes; Jerry P Radich; Andreas Hochhaus; Timothy P Hughes
Journal:  Leukemia       Date:  2019-06-17       Impact factor: 11.528

4.  Loss of constitutional heterozygosity in human astrocytomas.

Authors:  E Van de Kelft; K De Boulle; P Willems; J J Martin; P Selosse; B Van der Auwera
Journal:  Acta Neurochir (Wien)       Date:  1992       Impact factor: 2.216

Review 5.  Modulation of tumor cell gene expression and phenotype by the organ-specific metastatic environment.

Authors:  R Radinsky
Journal:  Cancer Metastasis Rev       Date:  1995-12       Impact factor: 9.264

6.  P53 tumor suppressor gene in chronic myelogenous leukemia: a sequential study.

Authors:  A Rovira; A Urbano-Ispizua; F Cervantes; M Rozman; J L Vives-Corrons; E Montserrat; C Rozman
Journal:  Ann Hematol       Date:  1995-03       Impact factor: 3.673

7.  Preliminary research on the p53 gene rearrangements in the evolution of chronic myelogenous leukemia to blast crisis.

Authors:  J C Chen; S M Liu; H B Fei; W L Gong
Journal:  J Tongji Med Univ       Date:  1994

8.  p53 gene rearrangements in chronic myelocytic leukemia.

Authors:  A Hernández; P Hernández; L Corral; A Muñiz; C Alaez; E Espinosa; O Fernández; G Martinez
Journal:  Ann Hematol       Date:  1993-02       Impact factor: 3.673

9.  Genetic analysis of p53 and RB1 tumor-suppressor genes in blast crisis of chronic myeloid leukemia.

Authors:  G Gaidano; A Serra; A Guerrasio; G Rege-Cambrin; U Mazza; G Saglio
Journal:  Ann Hematol       Date:  1994-01       Impact factor: 3.673

10.  Detection of p53 mutations using nonradioactive SSCP analysis: p53 is not frequently mutated in myelodysplastic syndromes (MDS).

Authors:  A Neubauer; C Brendel; D Vogel; C A Schmidt; I Heide; D Huhn
Journal:  Ann Hematol       Date:  1993-11       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.